Mr. Andre Larente reports

DIAGNOS ANNOUNCES CLOSING OF PRIVATE PLACEMENT

Diagnos Inc. has closed a non-brokered private placement of 5,228,668 units issued at a price of 30 cents per unit, for gross proceeds of $1,568,600.40. Together with the closing of the private placement of $2,499,999.90, announced on Sept. 20, 2024, the corporation has raised $4,068,600.30 in additional financing.

Each unit consists of:

• One common share;
• One common share warrant.

As part of the closing of the private placement, 5,228,668 warrants have been issued to the subscribers. Each warrant can be exercised to purchase one share at a price of 40 cents per share for a period of 18 months ending April 25, 2026.

In connection with the closing of the private placement, the corporation (i) paid cash commissions amounting to $18,207 and (ii) issued an aggregate number of 60,690 finders' warrants to three qualified firms acting at arm's length to the corporation. Each finder's warrant entitles the holder to purchase one share at an exercise price of 40 cents per share for a period of 18 months ending April 25, 2026.

The net proceeds from the private placement will be used to finance product development and commercialization of artificial-intelligence-based screening services, regulatory affairs as well as general and administrative operations.

All securities issued as part of the private placement are subject to a statutory hold period ending Feb. 26, 2025.

The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.